GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE292nnn/GSE292716/primaryOK200GenomicsHomo sapiensGenome binding/occupancy profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292716GEOGSEfalseSuper-enhancers-driven SOX4/SMAD3 enhances AXL signaling via membrane phospholipid remodeling to accelerate leukemia progression [ChIP-seq]Cancer often involves aberrant epigenetic activation. In CML-BP, super - enhancer - driven SOX4 and SMAD3 form an auto - regulatory axis. They co - regulate epigenome, activate AXL - related pathways, and mediate membrane phospholipid remodeling. Bemcentinib, an AXL inhibitor, can inhibit CML - BP progression. SOX4/SMAD3 are key factors and Bemcentinib a potential therapy.2026/05/15GSE292716GSM8864096GSM8864085GSM8864097GSM8864086GSM8864094GSM8864095GSM8864092GSM8864093GSM8864090GSM8864091GSM8864104GSM8864102GSM8864103GSM8864100GSM8864089GSM8864101GSM8864087GSM8864098GSM8864099GSM886408830209292716Homo sapiens[41721601]